Use this report to:

- Receive a detailed analysis of the present and future global market for pulmonary drug delivery technologies.
- Receive information on pulmonary drug delivery technologies currently available and in use.
- Receive information on the benefits of pulmonary drug delivery systems.
- Receive information on current inhalation drugs, asthma, and chronic obstructive pulmonary disease (COPD) and their related markets.

Highlights
- The global market for pulmonary drug delivery technologies reached $32.4 billion in 2013 and is expected to grow to $43.9 billion in 2018, with a compound annual growth rate (CAGR) of 6.2%.
- The dry powder inhalers (DPIs) market reached $17.5 billion in 2013 and is expected to grow to $31.5 billion in 2018, with a CAGR of 12.5%.
- The nebulizers market reached $685 7million in 2013 and is expected to grow to $893.5million in 2018, with a CAGR of 5.4%.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This BCC Research market research report, Pulmonary Drug Delivery Systems: Technologies and Global Markets, provides a detailed overview and detailed analysis of the present and future global market for pulmonary drug delivery technologies. This report analyzes in detail the pulmonary drug delivery technologies currently in use and that are available. This report includes products in this market and detailed analyses of the markets and competitive environments. It also analyzes current and future market prospects. The report provides a comprehensive review of emerging pulmonary drug delivery technologies, particularly with regard to inhaled drug delivery systems. The analysis reviews technological developments, product innovations and recent strategic industry activities of major players across different product categories. It reviews their strengths and weaknesses, opportunities and the threats facing various devices and drugs in this market space. The report also reviews developments already on the market, major issues involved in the research and development (R&D) of more effective drug/devices for drug delivery to the lungs and new products in development.

REASONS FOR DOING THE STUDY

Pulmonary drug delivery originated as a more relevant alternative for delivering drugs to the lungs. Respiratory conditions such as asthma, chronic obstructive pulmonary
(COPD) and emphysema are therapeutic areas of the pulmonary space. Recent technological advancements have applied the application of pulmonary devices to the
treatment of nonrespiratory conditions also such as diabetes and migraines. The recent trends and research in the formulating sector have grown tremendously and increased sales of dry powder inhalers (DPIs), and slowly replaced metered-dose inhalers (MDIs). Pulmonary delivery of drugs for the treatment of respiratory diseases gives a faster,
simpler and easier therapeutic effect compared to systemic treatments for these indications. In addition, it also reduces side effects associated with many drugs. Still,
understanding the trends in this market, and currently available drug/device combinations and improving them and eliminating risks and problems, will help in
faster, effective drug delivery to the lungs.

SCOPE AND FORMAT

The report reviews global markets for pulmonary drug delivery technologies and new developments, and forecasts trends for use of current drug/devices systems for
pulmonary drug delivery and safety and toxicology through 2018. The report presents important drug/device and technologies, latest developments, market share by
drug/device and drug and disease type, current products on the market, market share by company or product, and statistical information for types of respiratory diseases
prevalent worldwide, with special emphasis on the U.S. market. The report also includes current issues and trends affecting the industry including costs,
and factors influencing demand will be discussed. The report covers products in development, new technologies, trends, alliances, patents and mergers. The report
offers market data with respect to segments and geography. It also provides market trends with respect to drivers, restraints and opportunities.

INTENDED AUDIENCE
This report is an exhaustive study of the worldwide pulmonary drug delivery device market, giving crucial statistics and analysis on existing technologies, the latest trends,
market structure, market size, key drug segments, important trends in technology development, influencers, major opportunities, and market shares of key players and
inhaled drug/device and drug. This report may prove crucial for drug development companies in the pulmonary drug delivery space, such as potential investors in the
concerned sector. This report discusses drug/device currently being used for pulmonary drug delivery to the lungs, new developments surrounding these systems,
current spending trends and revenue prospects for these technologies. The report provides relevant market data for 2011 to 2018 and also covers commercial prospects
for pulmonary devices and current inhalers in use and their future.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers,
industry portals, interviews, government agencies, trade associations, industry news, and developments and access to paid databases. The base year of the report is 2013,
with forecast data provided through 2018. Historical, base year and forecast data are provided for each market segment of this report. The report provides a comprehensive
review of emerging pulmonary drug delivery technologies, particularly with regard to inhaled drug delivery systems (both drug and device combined). The analysis reviews
new technological developments, product innovations/introductions and recent strategic industry activities of major players across various product categories. Growth
rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D and current product growth.

Table Of Contents

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
SCOPE AND FORMAT 2
INTENDED AUDIENCE 3
METHODOLOGY 3
RELATED BCC RESEARCH REPORTS 3
ANALYST’S CREDENTIALS 4
BCC RESEARCH WEBSITE 4
DISCLAIMER 4

CHAPTER 2 SUMMARY 6
SUMMARY TABLE GLOBAL MARKET FOR PULMONARY DRUG DELIVERY
TECHNOLOGIES, THROUGH 2018 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL MARKET FOR PULMONARY DRUG DELIVERY
TECHNOLOGIES, 2011-2018 ($ MILLIONS) 7

CHAPTER 3 OVERVIEW 10
CURRENT MARKET TRENDS 10
TECHNOLOGY 10
TABLE 1 COMMONLY USED INHALED DRUGS 11
DRUG DELIVERY IN THE MODERN WORLD 11
INHALATION AS A TECHNIQUE 11
PULMONARY DRUG DELIVERY 12
TABLE 2 KEY FACTS 13
CONTRAINDICATIONS 13
TABLE 3 ADVANTAGES AND DISADVANTAGES OF MDIS 13
TABLE 4 ALTERNATIVE TO CFC MDIS 14
TABLE 5 MDIS PHASE-OUT DATES: UNITED STATES 14
DRY POWDER INHALERS 15
TABLE 6 COMMON DPI DEVICES 15
TABLE 7 DPI: ADVANTAGES AND DISADVANTAGES 16
Twisthaler 16
ACCESSORY DEVICES 16
NEBULIZERS 17
TABLE 8 ADVANTAGES AND DISADVANTAGES OF NEBULIZERS 17
PULMONARY CONDITIONS AND THERAPIES 17
RESPIRATORY SYSTEM 18
Lung 19
Role of Particle Size 20
SYSTEMIC AND LOCAL THERAPY 21
PULMONARY DRUG DELIVERY DEVICES 21
Device Characteristics 22
PULMONARY DRUG DELIVERY-THE FUTURE 26
INHALER DEVICES 27
TABLE 9 INHALER DEVICES AND CHARACTERISTICS 27
TABLE 10 DOSAGE FORMS—INHALERS 27
Available Products 28
TABLE 11 METERED DOSE INHALERS 28
TABLE 12 DRY POWDER INHALERS 29
COMMONLY USED INHALERS 29
TABLE 13 COMMON COPD INHALERS 29
INHALER-DRUG PROFILES 30
Aerosol Aztreonam (Cayston) 30
Dulera (Mometasone Furoate/Formoterol Fumarate Dihydrate) 31
Amikacin 32
Phase III INHALE Study Program 33
SYSTEMIC PULMONARY DELIVERY 33
Development of Exubera 34
Aerogen and Dance Pharmaceuticals 35
Safety Concerns 35
Future 35
Insulin-Exubera 36
MannKind's-Afrezza 36
Clinical Results 37
Study 171 37
Summary 37
Key Players 38
Pulmonary Drug Delivery-In a New Light 38
ASTHMA AND COPD-MAJOR RESPIRATORY DISEASE CONDITIONS 38
Asthma: Primary Respiratory Syndrome 38
Asthma and Obesity 40
TABLE 14 ASTHMA AND BIOMARKERS 41
Monitoring of Asthma 41
TABLE 15 INHALED STEROIDS (ASTHMA INHALERS) 42
TABLE 16 SYSTEMIC STEROIDS FOR ASTHMA TREATMENT 43
Delivery Methods 43
Chronic Obstructive Pulmonary Disease (COPD) 45
What is COPD? 46
COPD and Causative Factors 46
TABLE 17 COPD AND LUNG DAMAGE 48
Diagnosis of COPD 49
COPD and Treatment 50
METHODS OF DRUG DELIVERY 51
TABLE 18 COMMON COPD INHALERS ON THE MARKET 52
Aerosols 52
TABLE 19 COPD DRUGS ON THE MARKET 53
Formulations 53
INHALATION MARKET 54
Asthma Prevalence and Statistics 54
COPD and Incidence 55
Disease and Epidemiology 56
TABLE 20 INHALED DRUGS AND MARKET OPPORTUNITIES: CURRENT MARKET FOR
INHALED DRUGS, 2010 (% MARKET SHARE) 56

CHAPTER 4 PULMONARY DRUG DELIVERY SYSTEM 59
BENEFITS OF PULMONARY DRUG DELIVERY SYSTEMS 59
INHALER DEVICES 59
TABLE 21 INHALER DEVICES 60
PULMONARY DRUG DELIVERY TECHNOLOGIES 60
Technology Descriptions 60
Wide Array of Applications 60
TABLE 22 DRUGS AND THERAPEUTIC AGENTS ADMINISTERED BY INHALATION 61
INHALERS 61
Metered-dose Inhalers 61
MDIs-How Does It Work? 62
History 62
MDIs and Drug Delivery 63
Advantages and Challenges for MDIs 63
MDIs and Corticosteroids 63
TABLE 23 BRAND NAME METERED DOSE INHALERS (CORTICOSTEROIDS) 64
Bronchodilators 64
TABLE 24 BRAND NAME METERED DOSE INHALERS (BRONCHODILATORS) 64
Combination Inhalers 65
Nonsteroidal Inhalers 65
Problems with MDI Use and Spacers 65
Propellants and MDI Development 67
Montreal Protocol 67
Millions Use Inhalers for Asthma or COPD 67
TABLE 25 LIST OF INHALERS FOR ASTHMA AND COPD WITHOUT CFCS 68
TABLE 26 LIST OF METERED DOSE INHALERS AND INGREDIENTS 69
Fluticascone 69
Fluticasone and Salmeterol 70
Flunisolide 70
Beclomethasone 70
TRANSITION TO HFA PROPELLANTS 70
Chlorofluorocarbons (CFCs) 70
TABLE 27 THE SEVEN CFC INHALERS 71
Analgesic Inhalers 71
DRY POWDER INHALER (DPI) 72
TABLE 28 TYPES OF DPI DEVICES 74
Types of DPI Devices 74
TABLE 29 DPIS CURRENTLY ON THE MARKET 74
TABLE 30 TYPES OF DRY POWDER INHALERS (DPI) 76
DPIs for Children 76
Nebulizers 77
How Do They Work? 78
Use 78
TABLE 31 Nebulizers and Drugs 78
TABLE 32 NEBULIZERS: ADVANTAGES AND DISADVANTAGES 80
Ultrasonic Nebulizers 80
TABLE 33 VIBRATING MESH NEBULIZERS 81
Small Volume Nebulizers: Electronic Vibrating Mesh (VM)
Nebulizer 82
Factors Influencing Clinical Effectiveness of Inhalation Devices 82
CONCLUSIONS 83

CHAPTER 5 PULMONARY DRUG DELIVERY: DRUGS IN USE 85
CURRENT INHALATION DRUGS AND MARKET 85
AEROSOL AZTREONAM (CAYSTON) 85
DULERA (MOMETASONE FUROATE/FORMOTEROL FUMARATE DIHYDRATE) 86
PULMONARY DELIVERY OF SYSTEMIC DRUGS 87
Antibiotics 87
Analgesics 87
Anti-emetics 87
TABLE 34 THERAPEUTIC AGENTS ADMINISTERED BY INHALATION 87
Pulmonary Specific Vasodilators 88
Nicotine 88
Nebulizers for Pediatric Care 88
Vaccines 88
Obesity 89
Drugs and Inhalers: How Do They Work? 89
TABLE 35 SHORT-ACTING BRONCHODILATOR INHALERS 89
TABLE 36 LONG-ACTING BRONCHODILATOR INHALERS 90
Steroid Inhalers 90
TABLE 37 INHALED STEROID MEDICATIONS 90
TABLE 38 COMBINATION INHALERS 91
Breath-Activated Inhalers 91
Nebulizers 92
Pulmonary Delivery 92
Controlled Release 92
Formulations 95
Lactose Carrier Systems 95
Liposomes 95
PulmoSpheres 97
Biodegradable Polymers 98

CHAPTER 6 GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES 101
RESPIRATORY DISEASES 101
ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
MARKET 102
TABLE 39 ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
MARKET AND FORECAST, 2013 AND 2018 ($ MILLIONS) 102
FIGURE 1 ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
MARKET AND FORECAST, 2013 AND 2018 ($ MILLIONS) 103
GLOBAL RESPIRATORY DEVICES MARKET 103
COPD 104
DRUG DELIVERY MARKET 104
Drug Delivery Technologies and Market 104
European Drug Delivery Market 105
GLOBAL PHARMACEUTICAL MARKET 106
TABLE 40 GLOBAL PHARMACEUTICAL SALES AND FORECAST, THROUGH 2018 ($
BILLIONS) 106
FIGURE 2 GLOBAL PHARMACEUTICAL SALES AND FORECAST, 2011-2018 ($
BILLIONS) 106
Pharmaceutical Growth Rates 107
Emerging Markets 107
TABLE 41 TOTAL UNAUDITED AND AUDITED GLOBAL PHARMACEUTICAL MARKET
BY REGION, THROUGH 2017 ($ BILLIONS) 108
A Shift to Generics as Patents Expire 108
Growth in New Drugs 108
United States Pharmaceutical Industry 109
Top 20 Pharmaceutical Companies 110
TABLE 42 TOP 20 PHARMACEUTICAL COMPANIES, 2012 ($ MILLIONS) 110
TABLE 43 TWELVE LARGEST PHARMACEUTICAL COMPANIES, 2010 ($ MILLIONS) 111
DRUG DELIVERY 111
DRUG DELIVERY MARKET 112
Global Market 113
TABLE 44 KEY PLAYERS: DRUG DELIVERY TECHNOLOGIES MARKET 114
TABLE 45 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH
2018 ($ MILLIONS) 114
FIGURE 3 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($
MILLIONS) 115
TABLE 46 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($
MILLIONS) 116
FIGURE 4 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($
MILLIONS) 116
Oral Drug Delivery 116
TABLE 47 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH
2018 ($ MILLIONS) 117
FIGURE 5 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, 2012-2018 ($
MILLIONS) 117
Implantable and Injectable Drug Delivery 118
TABLE 48 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, THROUGH
2018 ($ MILLIONS) 118
FIGURE 6 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, 2011-2018
($ MILLIONS) 118
Transdermal Drug Delivery 119
TABLE 49 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET,
THROUGH 2018 ($ MILLIONS) 120
FIGURE 7 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET,
2011-2018 ($ MILLIONS) 120
Drug Delivery Market in the U.S. 120
TABLE 50 U.S. DRUG DELIVERY TECHNOLOGIES MARKET AND FORECAST,
THROUGH 2018 ($ MILLIONS) 121
FIGURE 8 U.S. DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS) 121
PULMONARY DRUG DELIVERY 122
TABLE 51 TOP ASTHMA AND COPD DRUGS 122
TABLE 52 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, THROUGH
2018 ($ MILLIONS) 122
FIGURE 9 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($
MILLIONS) 122
TABLE 53 LEADING PULMONARY DRUG DELIVERY PLAYERS 123
TABLE 54 PULMONARY DELIVERY TECHNOLOGIES MARKET IN THE U.S. AND
EUROPE, THROUGH 2018 ($ MILLIONS) 124
FIGURE 10 PULMONARY DRUG DELIVERY TECHNOLOGIES MARKET IN THE U.S. AND
EUROPE, 2011-2018 ($ MILLIONS) 124
ASTHMA AND COPD MARKET 125
TABLE 55 WORLDWIDE MARKET FOR TOP INHALED DRUGS: SALES AND FORECAST
2012-2013 ($ MILLIONS) 126
TABLE 56 UNITED STATES: TOP ASTHMA DRUGS SALES, 2012 AND 2013 ($
MILLIONS) 127
WHY PULMONARY DRUG DELIVERY? 127
Metered Dose Inhalers (MDIs) 128
TABLE 57 MARKET FOR MDI TECHNOLOGIES, THROUGH 2018 ($ MILLIONS) 129
FIGURE 11 MARKET FOR MDI TECHNOLOGIES, 2011-2018 ($ MILLIONS) 129
DRY POWDER INHALATION (DPI) 129
TABLE 58 DPI DEVICES 130
TABLE 59 MARKET FOR DPI TECHNOLOGIES, THROUGH 2018 ($ MILLIONS) 131
FIGURE 12 MARKET FOR DPI TECHNOLOGIES, 2011-2018 ($ MILLIONS) 131
Inhalers: Global Cost Comparison 132
GENERICS 133
Phase-out of CFC Inhalers and Historical Perspectives 133
CURRENT MARKET DYNAMICS 136
Rescue Inhalers 136
TABLE 60 TYPES OF INHALER UNITS SOLD WORLDWIDE, 2007 (%) 136
Combination Inhalers 137
TABLE 61 UNITED STATES: TOP ASTHMA DRUGS PRESCRIPTIONS, 2012 ($
MILLIONS) 137
Product Descriptions 137
Symbicort 137
ProAir and Qvar 137
Dulera 138
Spiriva 138
Advair 138
New Products 139
Breo Ellipta 139
Anoro Ellipta 139
Other Respiratory Development Programs 140
TABLE 62 NEW PRODUCTS IN THE RESPIRATORY DRUG MARKET, 2013 141
Ultibro Breezhaler 141
Impact on Advair Market in United States and Healthcare Changes 142
TABLE 63 ADVAIR SALES AND FORECAST, 2011-2015 ($ MILLIONS) 142
TABLE 64 GLAXOSMITHEKLINE: RESPIRATORY DRUGS PHARMACEUTICALS—THREE
MONTHS ENDED JUNE 30, 2013 ($ MILLIONS) 143
Arcapta Neohaler/Onbrez Breezhaler 143
Seebri Breezhaler 143
Theophylline 144
Flutiform 144
TABLE 65 SKYEPHARMA: PRODUCTS 144
TABLE 66 PARTNER NETWORK 145
Fluticasone/Salmeterol 145
TABLE 67 TOP SELLING INHALERS, 2010 ($ MILLIONS) 147
Tiotropium Bromide 147
Other Drugs 149
MAJOR PLAYERS 149
GlaxoSmithKline 149
TABLE 68 TOP SELLING DRUGS, 2010 ($ MILLIONS/+/- %) 149
CONCLUSION 150
Dry Powder Inhalation: A Promising Technology 150
TABLE 69 GROWTH AREAS FOR INHALERS 150
Generics for Advair: Teva 150
Nebulizers: Displaying Promising Growth 151
TABLE 70 GLOBAL RESPIRATORY DEVICE MARKET, THROUGH 2018 ($ MILLIONS) 151
FIGURE 13 GLOBAL RESPIRATORY DEVICE MARKET, 2011-2018 ($ MILLIONS) 151
TABLE 71 U.S. RESPIRATORY DEVICE MARKET, THROUGH 2018 ($ MILLIONS) 152
FIGURE 14 U.S. RESPIRATORY DEVICES MARKET, 2011-2018 ($ MILLIONS) 153
TABLE 72 GLOBAL MARKET FOR NEBULIZERS, THROUGH 2018 ($ MILLIONS) 153
FIGURE 15 GLOBAL MARKET FOR NEBULIZERS, 2011-2018 ($ MILLIONS) 154
Nebulizers on the Market 154

CHAPTER 7 GLOBAL MARKET TRENDS 157
GLOBAL TRENDS AND INHALER MARKET 157
ASIA 157
China 157
India 158
Iran 158
Regulatory Changes—Pulmonary Drug Delivery Hurdles 159
Increased Research and Development Efforts 159
Aerosol Delivery Market 159
Distribution Channels 160
GROWTH AND NEW DEVELOPMENTS 160
Pulmonary Disease Drug Market 161
Market Trends in Asia 161
Challenges and Future Development 162
Market Segmentation 162
Patient Involvement 163
Pulmonary Insulin 163
Exubera 164
Afrezza 164
INHALED SMALL MOLECULE THERAPEUTICS 165
TABLE 37 INHALED STEROID MEDICATIONS 165
SELECTED PROFILES OF DRUGS ON THE MARKET 166
Dulera 166
Arcapta (Indacaterol Maleate Inhalation Powder) 167
Daliresp 169

CHAPTER 8 KEY COMPANIES 171
KEY COMPANIES 171
KEY DEVELOPMENTS 171
SOME KEY COMPANIES AND DESCRIPTIONS 172
3M 172
ADAMIS PHARMACEUTICALS CORP. 172
AKELA PHARMA INC (CANADA) 173
ALEXZA PHARMACEUTICALS 173
ALKERMES 174
ALPHARX INC. 174
AOP ORPHAN PHARMACEUTICALS 175
APT PHARMACEUTICALS INC. 175
APTAR PHARMA 175
ARADIGM CORP. (USA) 176
ASTRAZENECA PLC (U.K.) 176
AVANIR PHARMACEUTICALS 177
AXENTIS PHARMA 177
BOEHRINGER INGELHEIM 177
TABLE 74 COPD PRODUCTS 178
CIPLA 178
TABLE 75 RANGE OF DRY POWDER INHALER DEVICES 179
CONSORT MEDICAL PLC (UK) 179
DAIICHI SANKYO 180
DEY L.P. (USA) 180
GILEAD SCIENCES 180
GLAXOSMITHKLINE PLC (UK) 181
GRACEWAY PHARMACEUTICALS, LLC (USA) 181
HOVIONE 181
INSPIRE PHARMACEUTICALS INC. 182
MANNKIND 182
MAP PHARMACEUTICALS 183
MERCK and CO. 183
MICRODOSE THERAPEUTX 184
MPEX PHARMACEUTICALS 184
NEKTAR THERAPEUTICS 184
NEXT SAFETY 185
NOVARTIS INTERNATIONAL AG 185
OPTINOSE 186
ORIEL THERAPEUTICS INC. 186
PEARL THERAPEUTICS 186
PFIZER 187
PHARMAXIS 187
PULMATRIX 188
RESPIRICS 188
SAVARA 188
SKYEPHARMA PLC (UK) 189
SUNOVION PHARMACEUTICALS INC. 189
SYNAIRGEN RESEARCH LTD 190
TEVA NORTH AMERICA 190
THERAVANCE 191
UNITED THERAPEUTICS 191
VECTURA GROUP PLC (UK) 192

CHAPTER 9 KEY DEVELOPMENTS AND COLLABORATIONS 194
HISTORICAL FACTS 194
COMPANIES: DEVELOPMENTS OR INNOVATIVE PRODUCTS 194
ADAMIS PHARMACEUTICALS 195
MICRODOSE THERAPEUTX 195
THERAVANCE AND GLAXOSMITHKLINE 195
Theravance 196
GlaxoSmithKline 196
MYLAN ANNOUNCES ACQUISITION OF RIGHTS TO NOVEL LAMA RESPIRATORY
COMPOUND FROM PFIZER 197
GSK'S INCRUSE 197
BOEHRINGER INGELHEIM (BI) 198
Civitas Therapeutics 199
PULMATRIX 199
MANNKIND'S INHALED INSULIN DRUG, AFREZZA 200
NOVARTIS 201
PEARL THERAPEUTICS 201
BAYER SCHERING PHARMA AG, GERMANY 202
DR. REDDY'S LABORATORIES 203
SUN PHARMA 203
SANDOZ 204
TEVA 205

CHAPTER 10 PATENT ANALYSIS 208
PATENT LANDSCAPE AND EFFECT ON SPENDING 208
TABLE 76 COPD KEY FACTS AND CHALLENGES 209
LATEST NEWS 210
ASTRAZENECA 210
REGULATORY ISSUES 210
NEW PATENT FILINGS 211
COMPETITIVE LANDSCAPE 212
TABLE 77 AREAS FOR DRUG DELIVERY IMPROVEMENTS 212
KEY PATENTS 213
Advair and Patent Issues 213
TABLE 78 PULMONARY DRUG DELIVERY TECHNOLOGIES AND KEY PATENTS 213
Proventil HFA 214
KEY FACTS 215
CONCLUSION 215

CHAPTER 11 REFERENCES 218

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

RNAi Drug Delivery : Technologies and Gobal Markets

RNAi Drug Delivery : Technologies and Gobal Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research report provides an in-depth assessment of recent progress and future opportunities for RNA interference (RNAi) players in major therapeutic and drug delivery areas, including infectious ...

Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

  • $ 4 795
  • Industry report
  • May 2014
  • by Transparency Market Research

nebulizer is a medical device used for the treatment of respiratory disorders (asthma, COPD and cystic fibrosis) that converts liquid medication into mist or aerosol. Thus, the medicine can easily reach ...

Needle-Free Drug Delivery Devices Market (Jet Injectors, Inhalers, Transdermal Patch and Novel Needle Technology) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Needle-Free Drug Delivery Devices Market (Jet Injectors, Inhalers, Transdermal Patch and Novel Needle Technology) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

  • $ 4 795
  • Industry report
  • May 2014
  • by Transparency Market Research

Needle-free drug delivery devices are novel techniques to introduce drugs into patient's body without invading the skin with a conventional needle. This technology provides effective drug delivery fo ...

Cytotoxic Drug Delivery

May 2014 $ 2 850

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.